Knowledge domain and emerging trends in empagliflozin for heart failure: A bibliometric and visualized analysis

OBJECTIVE: Empagliflozin (EMPA), a sodium-glucose cotransporter 2 inhibitor (SGLT2i), is recommended for all patients with Heart failure (HF) to reduce the risk of Cardiovascular death, hospitalization, and HF exacerbation. Qualitative and quantitative evaluation was conducted by searching relevant...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xuesong, Zhang, Ying, Hu, Yuanhui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9668858/
https://www.ncbi.nlm.nih.gov/pubmed/36407420
http://dx.doi.org/10.3389/fcvm.2022.1039348

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9668858/
https://www.ncbi.nlm.nih.gov/pubmed/36407420
http://dx.doi.org/10.3389/fcvm.2022.1039348

Ejemplares similares